Predictive Toxicological Analysis of Novel Prostate Cancer Drug

Predictive Toxicological Analysis of Novel Prostate Cancer Drug

Alvin Sherman Library

Prostate cancer is the second-leading cause of cancer-related death in men in the United States, claiming approximately 1 in 44 lives. While novel cancer therapies aim to selectively target cancer cells, minimizing damage to healthy tissues, these treatments can still cause significant side effects. The drug discovery process remains costly and time-intensive, with only 10-20% of compounds making it from clinical trials to market, often due to toxicity issues that arise during later-stage testing. To address this, computational methods in predictive toxicology can expedite drug development by assessing potential toxic effects early, reducing costs and risks. In this study, we utilized online predictive toxicology and drug discovery software to evaluate the toxicity of a novel cancer compound, comparing its toxicity profile to similar drugs. By analyzing drug-protein binding affinities, particularly those associated with both acute and long-term toxicity, we aim to identify potential risks early in the development process. This approach enhances the likelihood of developing safer, more effective therapies for prostate cancer, ultimately improving the drug discovery pipeline and increasing the chances of successful market approval.